Cell Isolation/ Separation Market worth $15.0 billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

CHICAGO, Dec. 11, 2020 /PRNewswire/ -- According to the new market research report "Cell Isolation/Cell Separation Market by Product (Reagents, Beads, Centrifuge), Cell Type (Human, Animal), Cell Source (Bone Marrow, Adipose), Technique (Filtration), Application (Cancer, IVD), End-User (Hospitals, Biotechnology) - Global Forecast to 2025", published by MarketsandMarkets, the global Cell Isolation Market size is projected to reach USD 15.0 billion by 2025 from USD 6.9 billion in 2020, at a 16.8% CAGR.

Browse in-depth TOC on "Cell Isolation/ Separation Market"

411 Tables 38 Figures 264 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=103931479

The increasing government funding for cell-based research, the increasing number of patients suffering from cancer and infectious diseases, technological advancements, and the growing focus on personalized medicine are the major factors driving the cell isolation markets growth. Emerging economies such as China and Japan are providing lucrative opportunities for the players operating in the market.

The consumables segment accounted for the largest share of the market, by product segment, in 2019

Based on product, the Cell Separation Market is segmented into consumables and instruments. In 2019, consumables segment accounted for the largest share. This can be attributed to the increasing investments by companies to develop technologically advanced products as well as the repetitive use of consumables.

Centrifugation- based segment accounted for the largest share of the cell isolation market, by technique segment, in 2019

Based on technique, the Cell Separation Market is segmented into centrifugation-based cell isolation, surface marker-based cell isolation, and filtration-based cell isolation. primarily due to the wide usage of this technique among end users. This technique is used on a large scale by biotech and biopharmaceutical companies as well as on a small scale by clinical research organizations and academia. The cost-effectiveness of this technique is another major reason for the large share of this segment. The growing demand for centrifugation techniques in biotech and biopharmaceutical companies is a major factor that is expected to drive the growth of this market segment in the coming years.

The biotechnology and biopharmaceutical companies segment accounted for the largest share in the market, by end user segment, in 2019

The cell isolation market is segmented into hospitals and diagnostic laboratories, biotechnology and biopharmaceutical companies, research laboratories and institutes, and other end users based on end users. In 2019, the biotechnology and biopharmaceutical companies segment accounted for the largest share. The widespread adoption of advanced instruments in cell-based experiments and cancer research in biotechnology and biopharmaceutical companies, as well as the increasing number of R&D facilities globally can be attributed for the large share of this end-user segment.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=103931479

North America is the largest regional market for cell isolation market

The Cell Separation Market is segmented into four regions, namely, North America, Europe, Asia Pacific and Rest of the world. In 2019, North America accounted for the largest share of the market. The large share of North America can be attributed to technological advancements, growth in the biotechnology and pharmaceutical industries, increasing prevalence of chronic and infectious diseases, and higher investments in cell-based research in the region.

The major players operating in this Cell Separation Market are Thermo Fisher Scientific, Inc. (US), Becton, Dickinson and Company Limited (US), Beckman Coulter Inc. (US).Merck KGaA (Germany), Terumo BCT (Japan), GE Healthcare (US), Bio- Rad Laboratories Inc. (US), Corning Inc. (US), Roche Diagnostics (Switzerland, Alfa Laval (Sweden), Miltenyl Biotech (Germany), pluriSelect Life Science (Germany), STEMCELL Technologies Inc. (Canada), Akadeum Life Sciences, Inc (US), Bio- Techne (US), Bio Legend (US) and Invent Biotechnologies (US).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=103931479

Browse Related Reports:

Single-Cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Consumables, Instruments), Technique (Flow Cytometry, NGS, PCR, Mass Spectrometry, Microscopy), Application (Research, Medical Application), End User - Global Forecasts to 2025

https://www.marketsandmarkets.com/Market-Reports/single-cell-analysis-market-171955254.html

Cell Expansion Market by Product (Reagent, Media, Flow Cytometer, Centrifuge, Bioreactor), Cell Type (Human, Animal), Application (Regenerative Medicine & Stem Cell Research, Cancer & Cell-based Research), End-User, and Region - Global Forecast to 2025

https://www.marketsandmarkets.com/Market-Reports/cell-expansion-market-194978883.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:

Mr. Aashish Mehra MarketsandMarkets INC. 630 Dundee Road Suite 430 Northbrook, IL 60062 USA: +1-888-600-6441 Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/cell-isolation-market.asp Visit Our Web Site: https://www.marketsandmarkets.com Content Source: https://www.marketsandmarkets.com/PressReleases/cell-isolation.asp

SOURCE MarketsandMarkets

See the rest here:
Cell Isolation/ Separation Market worth $15.0 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Global Induced Pluripotent Stem Cells (iPSCs) Market Expectable to Exceed Global Market Revenue, Size, Segments and Market Competition Trend to…

To get sample Copy of the report, along with the TOC, Statistics, and Tables please visit @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-induced-pluripotent-stem-cells-market

Some of the key players profiled in the report areFUJIFILM Holdings Corporation, Astellas Pharma Inc, Fate Therapeutics, Bristol-Myers Squibb Company, ViaCyte, Inc., CELGENE CORPORATION, Vericel Corporation, KCI Licensing, Inc, STEMCELL Technologies Inc., Japan Tissue Engineering Co., Ltd., Organogenesis Holdings Inc, Lonza, Takara Bio Inc., Horizon Discovery Group plc, Thermo Fisher Scientific.

Global Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

Induced pluripotent stem cells (iPSCs) market is segmented of the basis of derived cell type, application and end- user. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Key Developments in the Market:

In March 2018, Kaneka Corporation announced that they have acquired a patent in the Japan for the creation of the method to mass-culture pluripotent stem cells including iPS cells and ES cells. This will help the company to use the technology to produce high quality pluripotent stem cells which can be used in the drug and cell therapy.

In March 2015, Fujifilm announced that they have acquired Cellular Dynamics International. The main aim of the acquisition is to expand their business in the iPS cell-based drug discovery support service with the use of CDS technology. It will help them to product high- quality automatic human cells with the help of the induced pluripotent stem cells. This will help the company to be more competitive in the drug discovery and regenerative medicine.

Now Get 20% Discount on This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-stem-cells-market

Global Induced Pluripotent Stem Cells (iPSCs) Market Drivers:

Increasing R&D investment activities is expected to create new opportunity for the market.

Increasing demand for personalized regenerative cell therapies among medical researchers & healthcare is expected to enhance the market growth. Some of the other factors such as increasing cases of chronic diseases, growing awareness among patient, rising funding by government & private sectors and rising number ofclinical trialsis expected to drive the induced pluripotent stem cells (iPSCs) market in the forecast period of 2020 to 2027.

High cost of the induced pluripotent stem cells (iPSCs) and increasing ethical issues & lengthy processes is expected to hamper the market growth in the mentioned forecast period.

Table of Contents:

Access Full report @https://www.databridgemarketresearch.com/reports/global-induced-pluripotent-stem-cells-market

Reasons to purchase this report-:

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Original post:
Global Induced Pluripotent Stem Cells (iPSCs) Market Expectable to Exceed Global Market Revenue, Size, Segments and Market Competition Trend to...

Ca Bishops To Work w/ Govt on Vaccination Campaigns – Catholic Herald Online

The bishops of California have said that taking either the Moderna or Pfizer COVID-19 vaccine is not a sin, despite controversy that the vaccines are derived from embryonic stem cells.

In a December 3 statement, the California Catholic Conference of bishops stated that it, affirms that the imminent Pfizer and Moderna COVID-19 vaccines are morally acceptable and commits to working closely with Catholic health care ministries and Catholic Charities to promote and encourage COVID-19 vaccinations in collaboration with state and local governments and other entities, Catholic San Francisco reported.

The California bishops join many other bishops, including those of Alberta and Northwest Territories, who stated Dec. 2, The Catholic Church does certainly support and encourage ethical scientific research into the development of vaccines that will mitigate or even end the harm caused by this terrible disease.

However, the bishop of Fresno said a few weeks prior that there are concerns that the vaccine is derived from stem cells of an aborted baby.

Citing ethical concerns about the use of fetal cells in vaccine development, Bishop Joseph Brennan of Fresno has urged Catholics not to jump on the COVID-19 vaccine bandwagon, Los Angeles Times reported a few weeks ago.

Experts have explained that the vaccines by Moderna and Pfizer are made from proteins that do not come from embryonic or fetal tissues, ABC Action News stated.

Bishop Brennan explained, I wont be able to take a vaccine, I just wont, brothers and sisters, and I encourage you not to, if it was developed with material derived from stem cells of a baby who was aborted. Or material that was cast off from artificial insemination.

Kevin McCormack of the California Stem Cell Agency in Oakland explained that the Pfizer and the Moderna vaccines, use messenger RNA. So these are made from genetically tweaked proteins so they have nothing to do with embryonic tissue or fetal tissue, he said.

The AstraZeneca/Oxford vaccine has reportedly been developed from cell-lines originating from the cells of an aborted fetus in 1983, and the bishops of England and Wales have stated that the vaccine is still morally acceptable, according to The Catholic Universe.

View original post here:
Ca Bishops To Work w/ Govt on Vaccination Campaigns - Catholic Herald Online

CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV – GlobeNewswire

December 14, 2020 08:00 ET | Source: CRISPR Therapeutics AG

-Funding from the Bill & Melinda Gates Foundation will support research to enable CRISPR/Cas9-based therapies for HIV that can benefit patients worldwide-

ZUG, Switzerland and CAMBRIDGE, Mass., Dec. 14, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics(Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the receipt of a grant from the Bill & Melinda Gates Foundation to research in vivo gene editing therapies for the treatment of HIV.

While we have demonstrated the promise of CRISPR/Cas9 gene editing ex vivo in sickle cell disease and beta thalassemia, an in vivo approach to editing hematopoietic stem cells could allow the transformative benefit of CRISPR/Cas9 to reach a broader array of patients, including those in low resource settings that lack sufficient infrastructure for stem cell transplantation, said Tony Ho, M.D., Executive Vice President and Head of Research & Development at CRISPR Therapeutics. We look forward to working on new therapies that could contribute to the global effort to reduce the burden of HIV.

The grant builds upon CRISPR Therapeutics proprietary CRISPR/Cas9 gene editing technology and expertise in editing hematopoietic stem cells and contributes to efforts to accelerate transformative medicines for global health.

About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

CRISPR Forward-Looking Statement This press release may contain a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Ho in this press release, as well as regarding CRISPR Therapeutics expectations about any or all of the following: (i) the expected benefits of CRISPR Therapeutics research funded by the Bill & Melinda Gates Foundation and (ii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words believes, anticipates, plans, expects and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be favorable and predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics product candidates; potential impacts due to the coronavirus pandemic, such as the timing and progress of preclinical studies; uncertainties regarding the intellectual property protection for CRISPR Therapeutics technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics most recent annual report on Form 10-K, quarterly report on Form 10-Q, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at http://www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.

CRISPR THERAPEUTICS word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact: Susan Kim +1-617-307-7503 susan.kim@crisprtx.com

Media Contact: Rachel Eides WCG on behalf of CRISPR +1-617-337-4167 reides@wcgworld.com

See the original post:
CRISPR Therapeutics Receives Grant to Advance In Vivo CRISPR/Cas9 Gene Editing Therapies for HIV - GlobeNewswire

EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan – Business Wire

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--EdiGene, Inc., which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of the US Subsidiary, and Kehua Fan, M.D., as Head of Business Development. Both will report to Dr. Dong Wei, CEO of EdiGene.

Our company and R&D portfolio are entering into an exciting phase, as evidenced by the recent close of Series B financing and submission of the first gene editing product IND in China, said Dong Wei, Ph.D.CEO of EdiGene, Translating cutting-edge gene editing technologies into innovative solutions for patients requires deep internal R&D expertise as well as strong external partnerships. We are delighted to have Dr. Zhang and Dr. Fan join us at this significant stage of growth. Their extensive experience and proven track record in advancing innovative therapies, in addition to strong leadership skills, will help us to strengthen our portfolio and accelerate technology translation to help patients in need.

Dr. Zhang has around 20 years of experience in research and drug development in both industry and academia in the US. Prior to joining EdiGene, he was Vice President of KLUS Pharma and focused on cell therapy and new technologies. Before that, he was Director of Development at Cobalt Biomedicine leading CAR-T and other cell/gene therapy programs, and R&D Director at OvaScience developing stem cell-based products. Prior to that, he held various oncology research and development positions at Merrimack Pharmaceuticals and Archemix. Dr. Zhang completed his postdoctoral fellowship at Harvard Medical School/Boston Childrens Hospital. He received his B.S. degree from Henan Normal University, M.S. degree from Chinese Academy of Sciences and Ph.D. from University of New Hampshire.

Dr. Kehua Fan has over 15 years of Business Development, Clinical Development of innovative drugs and other healthcare industry experience with MNCs and biotech companies. Before EdiGene, she served as Head of Strategy and Partnership at Junshi Biosciences, in charge of pipeline development strategy focus on oncology, autoimmune and metabolic diseases along with external partnership. Before that, she held positions in business development, clinical development strategy and operation on various therapeutic areas at Quintiles, GSK, Sanofi and Pfizer. She started her career as a General Surgeon at Zhongshan Hospital of Chongqing. She received a masters degree in Cardiovascular Pharmacology from West China Medical Center of Sichuan University and a bachelors degree in Clinical Medicine from Soochow University.

About EdiGene, Inc EdiGene is a biotechnology company focused on leveraging the cutting-edge genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of genetic diseases and cancer. The company has established its proprietary ex vivo genome-editing platforms for hematopoietic stem cells and T cells, in vivo therapeutic platform based on RNA base editing, and high-throughput genome-editing screening to discover novel targeted therapies. Founded in 2015, EdiGene is headquartered in Beijing, with subsidiaries in Guangzhou, China and Cambridge, Massachusetts, USA. More information can be found at http://www.edigene.com.

See the article here:
EdiGene Expands Management Team by Appointment of Head of US Subsidiary Dr. Bo Zhang and Head of Business Development Dr. Kehua Fan - Business Wire

3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,…

December 11, 2020 08:41 ET | Source: ReportLinker

New York, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts, 2020-2030" - https://www.reportlinker.com/p05995354/?utm_source=GNW However, over time, it has been demonstrated that such cultures are unable to accurately mimic the natural (in vivo) microenvironment. Moreover, cells cultured in monolayers are both morphologically and physiochemically different from their in vivo counterparts. This leads to differences in viability, growth rate, and function. Additionally, in adherent 2D culture systems, only 50% of the cell surface is exposed to the culture medium, which limits cell-to-cell and cell-to-medium interactions. In fact, a study reported that 95% of drugs that exhibited efficacy in 2D culture models failed in in vivo studies / human trials.

Advances in biotechnology and materials science have enabled the development of a variety of 3-dimensional (3D) cell culture models. These systems have been demonstrated to be capable of more accurately simulating the natural tissue microenvironment and, thereby, can help overcome most of the challenges associated with 2D systems. In addition, there are certain complex 3D cell culture models that are likely to soon replace animal models. In other words, 3D cell cultures are able to better simulate the natural tissue microenvironments, thereby, serving as better in vivo models for use in experimental research, including drug discovery / toxicity testing, development of regenerative medicine, tissue engineering, and stem cell research. This is anticipated to drive the adoption of such solutions in the foreseen future. Moreover, in a recent study, perfused 3D culture systems were used to emulate human bronchial tissue and airway cells, in order to study infectious respiratory diseases. Further, 3D cell cultures and organoid-based screening systems are being developed to facilitate the study of the pathogenesis of the novel coronavirus and support ongoing drug development efforts on this front. Based on the current trend of use, we are led to believe that the COVID-19 pandemic is likely to result in an increased demand for such solutions, presenting lucrative opportunities for companies engaged in this domain. In this context, the overall 3D cell culture market is anticipated to witness substantial growth in the coming years.

SCOPE OF THE REPORT The 3D Cell Culture Market by Scaffold Format (Scaffold Based and Scaffold Free System), Products (Hydrogel / Extracellular Matrix (ECM), 3D Bioreactor, 3D Petri Dish, Hanging Drop Plate, Microfluidic System, Micropatterned Surface, Microcarrier, Organ-on-Chip, Solid Scaffold, and Suspension System), Application Areas (Cancer Research, Drug Discovery and Toxicology, Stem Cell Research, Tissue Engineering and Regenerative Medicine), Purpose (Research Use and Therapeutic Use), and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts (3rd Edition), 2020-2030 report features an extensive study of the current landscape and the likely future potential of 3D culture systems, over the next decade. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this field. In addition to other elements, the study includes: An insightful assessment of the current market landscape of companies offering various 3D cell culture systems, along with information on a number of relevant parameters, such as year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information related to the companies providing 3D culture related services, and associated reagents / consumables. A detailed assessment of the overall landscape of scaffold based products, along with information on a number of relevant parameters, such as status of development (under development, developed not commercialized, and commercialized), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold based products, highlighting year of establishment, size of employee base, and geographical presence. A detailed assessment of the overall landscape of scaffold free products, along with information on a number of relevant parameters, such as status of development (under development, developed and not commercialized, and commercialized), type of product (attachment resistant surfaces, suspension systems and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based and polymer based), and material used for fabrication. In addition, it presents details of the companies developing scaffold free products, highlighting their year of establishment, size of employee base, and geographical presence. A detailed assessment of the overall landscape of 3D bioreactors, along with information on a number of relevant parameters, such as type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. In addition, it presents details of the companies developing 3D bioreactors, highlighting year of establishment, size of employee base, and geographical presence. An insightful analysis, highlighting the applications (cancer research, drug discovery and toxicology, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used. Elaborate profiles of prominent players (shortlisted based on number of products being offered) that are engaged in the development of 3D cell culture products. Each company profile features a brief overview of the company, along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments, and an informed future outlook. An analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products. An analysis of the various partnerships related to 3D cell culture products, which have been established between 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations. An in-depth analysis of over 8,400 patents that have been filed / granted for 3D cell culture products, between 2015 and 2020, highlighting key trends associated with these patents, across type of patent, publication year, issuing authorities involved, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent characteristics and geography. It also includes a detailed patent valuation analysis. An in-depth discussion on the classification of 3D cell culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. An elaborate discussion on the methods used for fabrication of 3D matrices and scaffolds, highlighting the materials used, the process of fabrication, merits and demerits, and the applications of different fabrication methods. Insights from an industry-wide survey, featuring inputs solicited from various experts who are directly / indirectly involved in the development of 3D cell culture products.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the 3D cell culture market. Based on multiple parameters, such as business segment, price of 3D cell culture products, and likely adoption of the 3D cell culture products, we have provided informed estimates on the likely evolution of the 3D cell culture systems market in the mid to long term, for the time period 2020-2030. Our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers. In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industrys growth.

The opinions and insights presented in this study were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry and non-industry players: Brigitte Angres (Co-founder, Cellendes) Bill Anderson (President and CEO, Synthecon) Anonymous (President and CEO, Anonymous) Anonymous (Co-founder and Vice President, Anonymous) Scott Brush (Vice President, BRTI Life Sciences) Malcolm Wilkinson (Managing Director, Kirkstall) Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel) Tanya Yankelevich (Director, Xylyx Bio) Jens Kelm (Chief Scientific Officer, InSphero) Walter Tinganelli (Group Leader, GSI) Darlene Thieken (Project Manager, Nanofiber Solutions)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts views

While the focus has been on forecasting the market over the coming 10 years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED Who are the leading industry players engaged in the development of 3D cell culture products? What are the most popular 3D cell culture products? What are the different applications for which 3D cell culture products are currently being developed? What are the key factors that are likely to influence the evolution of this market? What is the trend of capital investments in the 3D cell culture systems market? Which partnership models are commonly adopted by stakeholders in this industry? How is the COVID-19 pandemic likely to impact the 3D cell culture systems market? How is the current and future opportunity likely to be distributed across key market segments? What are the anticipated future trends related to 3D cell culture systems market?

CHAPTER OUTLINES Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of 3D cell culture systems market and its likely evolution in the short to mid-term and long term. Chapter 3 provides a general introduction to 3D culture systems, covering details related to the current and future trends in the domain. The chapter highlights the different types of cell cultures, the various methods of cell culturing and their application areas. The chapter also features a comparative analysis of 2D and 3D cultures, as well as highlights the current need and advantages of 3D culture systems.

Chapter 4 provides an overview of the classification of 3D culture systems, categorized as scaffold based systems (hydrogels / ECMs, solid scaffolds, micropatterned surfaces and microcarriers), scaffold free systems (attachment resistant surfaces, suspension systems and microfluidic systems) and 3D bioreactors. It also highlights, in detail, the underlying concepts, advantages and disadvantages of the aforementioned products.

Chapter 5 presents summaries of different techniques that are commonly used for fabrication of 3D matrices and scaffolds. It further provides information on the working principle, benefits and limitations associated with each method. In addition, the chapter features key takeaways from various research studies focused on matrices fabricated using the aforementioned methods.

Chapter 6 includes information on close to 160 industry players offering various 3D cell culture products. It features detailed analyses of these companies based on year of establishment, size of employee base, geographical presence, 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactors), and type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems). In addition, the chapter provides information the companies that offer 3D culture related services and associated reagents / consumables. It also highlights the contemporary market trends in four schematic representations, which include [A] a heat map representation illustrating the distribution of developers based on type of 3D cell culture format and company size, [B] an insightful tree map representation of the developers, distributed on the basis of type of product and company size, and [C] a world map representation highlighting the regional distribution of developer companies.

Chapter 7 includes information on close to 150 scaffold based products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed and not commercialized, and commercialized, type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, and microcarriers), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold based products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 8 includes information on more than 60 scaffold free products that are either commercialized or under development. It features detailed analyses of these products based on status of development (under development, developed not commercialized, and commercialized, type of product (attachment resistant surfaces, suspension systems, and microfluidic systems), source of 3D cultured cells (natural and synthetic), method used for fabrication (human based, animal based, plant based, and polymer based), and material used for fabrication. The chapter also highlights the contributions of various companies developing scaffold free products, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 9 includes information on more than 100 3D bioreactors that are either commercialized or under development. It features detailed analyses of these products based on the type of 3D bioreactor (single-use, perfusion, fed-batch, and fixed-bed), and typical working volume. The chapter also highlights the contributions of various companies developing 3D bioreactors, presenting a detailed analysis based on their year of establishment, size of employee base and geographical presence.

Chapter 10 presents a detailed overview and analysis on the most popular application areas, which include cancer research, drug discovery and toxicity screening, stem cell research, tissue engineering and regenerative medicine) for which various 3D cell culture products are being developed / used.

Chapter 11 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold based products (offering at least five hydrogel / ECM products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 12 features elaborate profiles of prominent players that are either engaged in the development or have developed popular scaffold free products (offering at least three organ-on-chip products). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 13 features elaborate profiles of prominent players that are either engaged in the development or have developed 3D bioreactors (offering at least two bioreactors). Each company profile features a brief overview of the company along with information on year of establishment, number of employees, location of headquarters and key members of the executive team, details of their respective product portfolio, recent developments and an informed future outlook.

Chapter 14 features an analysis of the investments made in the period between 2015 and 2020, including seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, at various stages of development in small and mid-sized companies (established after 2005; with less than 200 employees) that are engaged in the development of 3D cell culture products, highlighting the growing interest of the venture capital community and other strategic investors, in this domain.

Chapter 15 features in-depth analysis and discussion of the various partnerships inked between the players in this market, during the period, 2015 and 2020 (till September), based on several parameters, such as year of agreement, type of partnership (product development / commercialization agreements, product integration / utilization agreements, product licensing agreement, research and development agreements, distribution agreements, acquisitions, joint venture and other agreements), 3D cell culture format (scaffold based products, scaffold free products and 3D bioreactor), type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems and microfluidic systems), and most active players. It also provides the regional distribution of players involved in the collaborations.

Chapter 16 provides an in-depth patent analysis presenting an overview of how the industry is evolving from the R&D perspective. For this analysis, we considered over 8,400 patents that have been filed / granted for 3D cell culture products, since 2015, highlighting key trends associated with these patents, across type of patents, publication year, geographical location, type of applicants, issuing authorities involved, CPC symbols, emerging focus areas, leading players (in terms of number of patents granted / filed in the given time period), patent characteristics and geography. It also includes a detailed patent valuation analysis.

Chapter 17 presents an insightful market forecast analysis, highlighting the likely growth of 3D cell culture systems market, for the time period 2020-2030. In order to provide an informed future outlook, our projections have been segmented on the basis of [A] 3D cell culture scaffold (scaffold based systems, scaffold free systems, and 3D bioreactors), [B] type of product (hydrogels / ECMs, micropatterned surfaces, solid scaffolds, microcarriers, attachment resistant surfaces, suspension systems, and microfluidic systems), [C] area of application (cancer research, drug discovery / toxicity testing, stem cell research, and regenerative medicine / tissue engineering), [D] purpose (research use and therapeutic use), [E] key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA (Middle East and North Africa) and RoW (Rest of the World)), and [F] leading product developers.

Chapter 18 presents insights from the survey conducted for this study. We invited over 150 stakeholders involved in the development of 3D cell culture systems. The participants, who were primarily Founder / CXO / Senior Management level representatives of their respective companies, helped us develop a deeper understanding on the nature of their products / services and the associated commercial potential.

Chapter 19 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the 3D cell culture systems market.

Chapter 20 is a collection of transcripts of interviews conducted with various stakeholders in the industry. The chapter provides a brief overview of the companies and details of interviews held with Brigitte Angres (Co-founder, Cellendes), Bill Anderson (President and CEO, Synthecon), anonymous (President and CEO, Anonymous), anonymous (Co-founder and Vice President, Anonymous), Scott Brush (Vice President, BRTI Life Sciences), Malcolm Wilkinson (Managing Director, Kirkstall), Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel), Tanya Yankelevich (Director, Xylyx Bio), Jens Kelm (Chief Scientific Officer, InSphero), Walter Tinganelli (Group Leader, GSI), and Darlene Thieken (Project Manager, Nanofiber Solutions) Chapter 21 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 22 is an appendix, which contains the list of companies and organizations mentioned in the report. Read the full report: https://www.reportlinker.com/p05995354/?utm_source=GNW

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Originally posted here:
3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions : Industry Trends and Global Forecasts,...

Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress – GlobeNewswire

December 11, 2020 09:00 ET | Source: Akari Therapeutics Plc

NEW YORK and LONDON, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced financial results for the third quarter ended September 30, 2020, as well as recent clinical progress.

With the imminent opening of our Phase III trial in pediatric patients with HSCT-TMA in Europe and a clear regulatory path in the U.S. and Europe for our Phase III study in patients with BP, we are now in the exciting position of progressing two Phase III programs in orphan diseases in which there are no approved treatments, said Clive Richardson, Chief Executive Officer of Akari Therapeutics.

Third Quarter 2020 and Recent Clinical Highlights

Akaris two lead programs in BP and HSCT-TMA are in Phase III development. The Company also has programs addressing lung and ophthalmology diseases.

Phase III clinical trial in patients with BP

Phase III clinical trial in pediatric patients with HSCT-TMA

Ophthalmology program

Lung program

PNH - long term data

Third Quarter 2020 Financial Results

COVID-19 Corporate Update

Akaris clinical trial sites are based in areas currently affected by the global outbreak of the COVID-19 pandemic, and public health epidemics such as this can adversely impact the Companys business as a result of disruptions, such as travel bans, quarantines, and interruptions to access the trial sites and supply chains, which could result in material delays and complications with respect to research and development programs and clinical trials. Moreover, as a result of the pandemic, there is a general unease of conducting unnecessary activities in medical centers. As a consequence, the Companys ongoing trials have been halted or disrupted. For example, the Phase I/II clinical trial in patients with AKC study has been halted and recruitment in the Phase III clinical trial in pediatric patients with HSCT-TMA has been and may continue to be delayed. It is too early to assess the full impact of the coronavirus outbreak on trials for nomacopan, but coronavirus is expected to affect Akaris ability to complete recruitment in the original timeframes. The extent to which the COVID-19 pandemic impacts operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration and continued severity of the outbreak, and the actions that may be required to contain the coronavirus or treat its impact. In particular, the continued spread of COVID-19 globally, could adversely impact the Companys operations and workforce, including research and clinical trials and the ability to raise capital, could affect the operations of key governmental agencies, such as the FDA, which may delay the development of the Companys product candidates and could result in the inability of suppliers to deliver components or raw materials on a timely basis or at all, each of which in turn could have an adverse impact on the Companys business, financial condition and results of operation.

About Akari Therapeutics

Akari is a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression. Akari's lead drug candidate, nomacopan (formerly known as Coversin), is a C5 complement inhibitor that also independently and specifically inhibits leukotriene B4 (LTB4) activity.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance upon the Companys forward looking statements. Except as required by law, the Company undertakes no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this press release. These forward-looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control. Such risks and uncertainties for our company include, but are not limited to: needs for additional capital to fund our operations, our ability to continue as a going concern; uncertainties of cash flows and inability to meet working capital needs; an inability or delay in obtaining required regulatory approvals for nomacopan and any other product candidates, which may result in unexpected cost expenditures; our ability to obtain orphan drug designation in additional indications; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for nomacopan and any other product candidates and unexpected costs that may result therefrom; difficulties enrolling patients in our clinical trials; our ability to enter into collaborative, licensing, and other commercial relationships and on terms commercially reasonable to us; failure to realize any value of nomacopan and any other product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing product candidates; the approval by the FDA and EMA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for nomacopan may not be as large as expected; risks associated with the impact of the COVID-19 pandemic; risks associated with theSECinvestigation; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third party manufacturers or establish commercial scale manufacturing capabilities; the inability to timely source adequate supply of our active pharmaceutical ingredients from third party manufacturers on whom the company depends; unexpected cost increases and pricing pressures and risks and other risk factors detailed in our public filings with theU.S. Securities and Exchange Commission, including our most recently filed Annual Report on Form 20-F filed with theSEC. Except as otherwise noted, these forward-looking statements speak only as of the date of this press release and we undertake no obligation to update or revise any of these statements to reflect events or circumstances occurring after this press release. We caution investors not to place considerable reliance on the forward-looking statements contained in this press release.

AKARI THERAPEUTICS, Plc

CONDENSED CONSOLIDATED BALANCE SHEETS As of September 30, 2020 and December 31, 2019 (in U.S. Dollars, except share data)

AKARI THERAPEUTICS, Plc

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - UNAUDITED For the Three and Nine Months Ended September 30, 2020 and September 30, 2019 (in U.S. Dollars)

For more information Investor Contact:

Peter Vozzo Westwicke (443) 213-0505 peter.vozzo@westwicke.com

Media Contact:

Sukaina Virji / Lizzie Seeley Consilium Strategic Communications +44 (0)20 3709 5700 Akari@consilium-comms.com

Link:
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress - GlobeNewswire

Researchers identify the origin of a deadly brain cancer – McGill Newsroom

Finding could lead to potential therapies

Researchers at McGill University are hopeful that the identification of the origin and a specific gene needed for tumour growth could lead to new therapeutics to treat a deadly brain cancer that arises in teens and young adults. The discovery relates to a subgroup of glioblastoma, a rare but aggressive form of cancer that typically proves fatal within three years of onset. The findings are published in the latest issue of the journalCell.

To complete their study, the research team, led by McGills Dr. Nada Jabado, Professor of Pediatrics and Human Genetics and Dr. Claudia Kleinman, Assistant Professor of Human Genetics, assembled the largest collection of samples for this subgroup of glioblastoma and discovered new cancer-causing mutations in a gene called PDGFRA, which drives cell division and growth when it is activated.

The researchers noted that close to half of the patients at diagnosis and the vast majority at tumour recurrence had mutations in this gene, which was also unusually highly expressed in this subgroup of glioblastoma. We investigated large public datasets of both children and adult patients in addition to those we had generated from patients samples in the lab and came to the same conclusion, PDGFRA was unduly activated in these tumours. This led us to suspect this kinase plays a major role in tumour formation explains Dr Carol Chen, a postdoctoral fellow, and Shriya Deshmukh an MD-PhD candidate in the Jabado lab and the studys co-first authors.

Employing a big data resource generated by their team using new technologies that measure the levels of every gene in thousands of individual cells, they were able to discover that this brain tumour originates in a specific type of neuronal stem cell. We used single cell analyses to create an atlas of the healthy developing brain, identifying hundreds of cell types and their traits, explains Selin Jessa, a PhD student in the Kleinman lab and co-first author on this study. Since these brain tumours retain a memory, or footprint, of the cell in which they originated, we could then pinpoint the most similar cell type for these tumours in the atlas, in this case, inhibitory neuronal progenitors that arise during fetal development or after birth in specific structures of the developing brain, adds Dr. Kleinman who leads a computational research lab at the Lady Davis Institute at the Jewish General Hospital.

An unexpected finding

The researchers note that the PDGFRA gene is not usually turned on in this neuronal stem cell population. By using sequencing technologies that measure how a cells DNA is spatially organized in 3D, notes Djihad Hadjadj, a postdoctoral fellow in the Jabado lab and the studys co-first author, We found that, exquisitely in this neuronal stem cell, the DNA has a unique structure in the 3D dimension that allows the PDGFRA gene to become activated where it shouldnt be, ultimately leading to cancer.

The finding is also important in properly classifying the tumour. Previously, this tumour type was classified as a glioma, because under the microscope, it resembles glial cells, one of the major cell types in the brain, says Dr. Jabado, who holds a CRC Tier 1 in Pediatric Oncology in addition to being a clinician scientist at the Montreal Childrens Hospital and leading a research lab focused on studying brain tumours at the Research Institute of the McGill University Health Centre. Our work reveals that this is a case of mistaken identity. These tumours actually arise in a neuronal cell, not a glial cell.

A hope for potential treatment

PDGFRA is targetable by drugs that inhibit its activity, and there are, in fact already approved drugs that target it for other cancers for which mutations in this gene are responsible, such as gastrointestinal stromal tumours. This offers hope for work into finding targeted therapies for this group of deadly brain tumours, note the researchers.

The combined studies of the genome, including at the single cell level and the genomic architecture in 3D of the tumour compared to the normal developing brain, were crucial in this study. They helped identify the specific timepoints during development where the cell is vulnerable to the cancer-driver event in these gliomas, which were revealed to be neuronal tumours. Importantly, the authors unravel genetic events that could lead to targeted therapy in a deadly cancer. Our findings provide hope for improved care in the near future for this tumour entity as these exquisite vulnerabilities may pinpoint to treatments that would preferentially attack the bad cells, say Drs. Jabado and Kleinman, who have joined efforts in the fight against deadly brain tumour. Stalled development is at the root of many of these cancers. The same strategy will prove important to unravel the origin, identify and exploit specific vulnerabilities, and orient future strategies for earlier detection in other brain tumour entities affecting children and young adults.

This study was made possible in large part thanks to support from the Genome Canada LSARP project Tackling Childhood Brain Cancer at the root to improve survival and quality of life, which includes funding from Genome Canada, Genome Quebec, CIHR and other sources, as well as the Fondation Charles-Bruneau and the National Institutes of Health.

Histone H3.3G34-Mutant Interneuron Progenitors Co-optPDGFRAfor Gliomagenesis, by C. Chen, S. Deshmukh, S. Jessa, D. Hadjadj, C. Kleinman, N. Jabado, et al, was published in the journalCellon December 10, 2020. DOI:https://doi.org/10.1016/j.cell.2020.11.012

Read more here:
Researchers identify the origin of a deadly brain cancer - McGill Newsroom

Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen – The…

Summary of the Cancer Stem Cell Therapy Market Report

Rise in R&D activities across the globe, increase in demand and growth across several application areas are some of the factors boosting the growth of the market.

Key Companies

AVIVA BioSciences AdnaGen Advanced Cell Diagnostics Silicon Biosystems

Cancer Stem Cell Therapy Market by Type

Autologous Stem Cell Transplants Allogeneic Stem Cell Transplants Syngeneic Stem Cell Transplants Others

Cancer Stem Cell Therapy Market by Application

Hospital Clinic Medical Research Institution

The major regional market covered under the scope of the study are APAC, North America, Europe, South & Central America, Africa and the Middle East. Singapore, Russia, Mexico, South America, Canada, France, the U.S., Germany, Africa, Italy, the United Kingdom, India, China, the Middle East, Central America, Japan, South America, Taiwan, and South Korea among others.

To know more about the report, visit @https://decisivemarketsinsights.com/cancer-stem-cell-therapy-market/58996063/request-sample

Cancer Stem Cell Therapy Market Overview, Key Trends Market Dynamics

Growth across various application areas and major geographies, growing R&D activities and rising demand are some of the key factors currently driving this market. The market would witness significant growth throughout the forecast period. Other factors are increasing the rate of adoption and improving the product that drives the demand at a fast pace. At present, i.e. 2020, the effect of COVID -19 can be seen; however, the market will soon recover in the coming years probably by 2021.

Regional Coverage of Global Cancer Stem Cell Therapy Market

Mexico, Canada, and the United States are the major countries covered under North America Italy, UK, Germany, Italy, UK, France, UK, Russia are covered under Europe Taiwan, India, China, South Korea, Singapore, Japan, and Others are covered under Asia Pacific Rest of the World (RoW) covers Africa, South America & Central America and the Middle East COVID -19 Impact Analysis

The report also offers a detailed insight of COVID -19 impact analysis:

Before COVID -19 Present Scenario Post recovery of COVID -19

Inquire Before Purchasing the report, visit @https://decisivemarketsinsights.com/cancer-stem-cell-therapy-market/58996063/pre-order-enquiry

Table of Content

Customization can be availed on Request:

Chapter 1: Introduction and Scope Chapter 2: Key Company Profiles Chapter 3: Remarks, Share and Forecast across type, application and geography Chapter 4: Market Remarks of Asia Pacific region Chapter 5: Market Remarks of Europe region Chapter 6: Market Remarks of Asia Pacific region Chapter 7: Market Remarks of North America region Chapter 8: Market Remarks of Middle East and Africa region Chapter 9: Key Important features of the market Chapter 10: Key trends of the market and the market Opportunities Chapter 11: Strategies to be adopted by the key players

Continued.

Key Pointers of the Report

For each and every segment and its sub-segment, market share and growth rate are given Estimation and forecast provided from 2020 to 2027 Data triangulation method has been followed to conclude the market The study also includes the strategies to be followed by the major players COVID -19 impact analysis was also covered under the framework of impact analysis

Supplementary Pointers of the Report:

Stated below are some of the added key points of the report:

SWOT Analysis Porters Five Analysis Value Chain Analysis Market Attractiveness Analysis PEST Analysis

To Inquire about the Discount available with the report, visit @https://decisivemarketsinsights.com/cancer-stem-cell-therapy-market/58996063/request-discount

Note: Year End Discount If you purchase the report this year Flat 15% instant discount 20% discount on 2nd report 1 Year consultation and 10 % free customization

Kindly contact us and our expert will get back to you within 30 minutes: Decisive Markets Insights Sunil Kumar Sales Head Email sales@decisivemarketsinsights.com US +18317045538 UK +44125663604

Follow this link:
Cancer Stem Cell Therapy Market Revenue, Global Forecast, Cost, Key Participants and Emerging Trends and Key Players-AVIVA BioSciences , AdnaGen - The...

Stem Cell therapist to visit Jefferson salon for special event – Marshall News Messenger

JEFFERSON Guests to Salon Rouge Spa in Jefferson next Friday will have a chance to consult with stem cell therapist Gail McBride and her team of doctors and specialists, Salon owner Brooke Bradley-LaFleur said Friday.

One of my employees heard her ad on the radio and has been having shoulder pain, LaFleur said. She looked into and realized that Gail was planning to have knee surgery after suffering knee pain for years but instead she had the stem cell injection and was able to avoid surgery. Gail brought me pictures of her x-rays before and after the stem cell injection and you could clearly see a huge difference. It was amazing.

LaFleur said after talking with McBride, who owns Longview Regeneration and Wellness Center, that Jeffersonians would enjoy a chance to learn about possible alternatives to surgery for issues like joint pain and skin rejuvenation through stem cell therapy.

What I really love is helping people avoid having to have surgery, LaFleur said. Gail and her team of specialists and doctors will come down and offer consultations and then decide how to proceed. Stem cell therapy can also be used for anti-aging against wrinkles. Some people need just one injection and others need more, depending on the location and severity of the issue they are treating.

The event with McBride at Salon Rouge is set for 5 to 7 p.m. on Friday.

LaFleur said masks will be worn and social distancing will be enforced to make sure guests remain safe during the event.

Refreshments will be served and gift certificates will be awarded during the event.

The rest is here:
Stem Cell therapist to visit Jefferson salon for special event - Marshall News Messenger